Boardroom Alpha
8-K primary document
AVTR · Current Report (Form 8-K) · Filed February 11, 2026

Avantor Inc8-K exhibit

a2025q4segmentrealignment-.htm
Document

Exhibit 99.2
avantorlogoa08.jpg
Avantor, Inc.
Summary Segment Information (unaudited)
(dollars in millions)
The unaudited reclassified segment financial information below is provided to reflect the change in the Company's reporting segments effective during the first quarter of 2026. The Company did not operate under the new structure for any of these prior periods and will begin to report comparative results under the new structure effective with the filing of its Quarterly Report on Form 10-Q for the quarter ending March 31, 2026.
Reportable segment data on an annual basis for the years ended December 31, 2025, 2024, and 2023 and a quarterly basis for the year ended December 31, 2025, are presented in the tables below:
Year ended December 31,
202520242023
Net sales:
Bioscience & Medtech Products$1,822.0 $1,788.5 $1,872.0 
VWR Distribution & Services4,730.2 4,995.1 5,095.2 
Total$6,552.2 $6,783.6 $6,967.2 
Adjusted operating income:
Bioscience & Medtech Products$485.5 $503.8 $551.5 
VWR Distribution & Services542.7 652.5 718.2 
Corporate(70.4)(66.5)(57.9)
Total$957.8 $1,089.8 $1,211.8 
Year ended December 31, 2025
First QuarterSecond QuarterThird QuarterFourth QuarterTotal
Net sales:
Bioscience & Medtech Products$426.4 $475.9 $448.8 $470.9 $1,822.0 
VWR Distribution & Services1,155.0 1,207.5 1,175.0 1,192.7 4,730.2 
Total$1,581.4 $1,683.4 $1,623.8 $1,663.6 $6,552.2 
Adjusted operating income:
Bioscience & Medtech Products$114.5 $131.4 $119.3 $120.3 $485.5 
VWR Distribution & Services147.9 141.6 132.0 121.1 542.7 
Corporate(19.6)(20.8)(14.0)(16.0)(70.4)
Total$242.8 $252.2 $237.3 $225.4 $957.8 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer